RIVM will calculate temporary background value for PFAS in soil In the coming weeks, RIVM will derive a temporary background value for PFAS in Dutch soil. This will be done based on measurement data from the provinces in the Netherlands.
RIVM reaction to farmers protest on 16 October 2019 On 16 October, farmers protested in the vicinity of RIVM in Bilthoven. The Director-General of RIVM, Hans Brug, was present at the protest site.
Openness about nitrogen There is concern about the current approach to nitrogen and the proposed measures; these concerns have been expressed in Dutch society as a whole and amongst farmers in particular.
Cold meat cuts probable source of 20 listeria cases RIVM has identified a cluster of 20 patients diagnosed with listeria over the past 2 years who are most likely to have been infected with an identical strain.
WHO Chemical Risk Assessment Workshop on new and emerging risks to human health from chemicals RIVM is hosting an international workshop on new and emerging risks from chemicals on 20 and 21 February 2019.
Possible health risks due to exposure to chromium-6 at tROM project Tilburg Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.
Kick off European Project VITAL: Vaccines and InfecTious diseases in the Ageing popuLation Recently, the EU-sponsored Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project was launched.
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.